Multiplex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) 
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
Overview
Properties
- Product No.CMN576Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryCD & Adhesion molecule
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 86-101 | 92 |
| EDTA plasma(n=5) | 96-104 | 99 |
| heparin plasma(n=5) | 78-97 | 82 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-93% | 78-96% | 95-105% | 80-93% |
| EDTA plasma(n=5) | 97-105% | 89-102% | 80-96% | 81-105% |
| heparin plasma(n=5) | 93-102% | 89-96% | 88-101% | 86-96% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by CBA (Cytometric Bead Array) in the sample and corresponding value of MFI (Median Fluorescence Intensity). Flow Cytometer was used to determine and calculate the sample concentration.
Giveaways
Increment services
Citations
- Serum irisin levels in new-onset type 2 diabetesPubMed: 23369227
- Lower circulating irisin is associated with type 2 diabetes mellitusPubmed: 23619195
- Inconsistency in circulating irisin levels: what is really happeningPubmed:24459033
- Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in micePubmed:25199621
- Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese micePubmed:25576856
- Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysisPubMed: 25494632
- Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancyPubMed: 26689349
- Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-AnalysisPubmed:27300472
- Physiology and role of irisin in glucose homeostasis.pubmed:28211512
- Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese micepubmed:27638193
- Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma pubmed:28867187
- Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male micePubmed:29351550
- The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.Pubmed:29522296
- Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative …Doi: 10.1016/j.redox.2018.10.019
- Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute …Pubmed: 31250660
- Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancyPubmed: 31590596
- Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitisPubmed: 32199226
- Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver InjuryPubmed: 31976032
- Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular CarcinomaPubmed: 31976024
- The myokine Irisin: localization and effects in swine late medium and large antral ovarian folliclePubmed: 33120167
- The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway
- Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c …
- Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients33755963
- Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo …34822430
- Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice34370270
- Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parametersPubmed:35604540
- Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent …Pubmed:35653888
- Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin …